GenMont Biotech Inc (3164) - Total Liabilities
Based on the latest financial reports, GenMont Biotech Inc (3164) has total liabilities worth NT$297.05 Million TWD (≈ $9.36 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GenMont Biotech Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
GenMont Biotech Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how GenMont Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GenMont Biotech Inc (3164) total assets.
GenMont Biotech Inc Competitors by Total Liabilities
The table below lists competitors of GenMont Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PanGen Biotech Inc
KQ:222110
|
Korea | ₩2.74 Billion |
|
Toplus Global Co Ltd
TWO:3522
|
Taiwan | NT$1.65 Billion |
|
OS Therapies Incorporated
NYSE MKT:OSTX
|
USA | $4.25 Million |
|
MeVis Medical Solutions AG
XETRA:M3V
|
Germany | €5.34 Million |
|
Histeel
KO:071090
|
Korea | ₩128.70 Billion |
|
Better Life Group Co Ltd
TW:1805
|
Taiwan | NT$369.27 Million |
|
Oceanpal Inc
NASDAQ:OP
|
USA | $4.10 Million |
|
Kinatico Ltd
AU:KYP
|
Australia | AU$6.19 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down GenMont Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of GenMont Biotech Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GenMont Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GenMont Biotech Inc (2003–2025)
The table below shows the annual total liabilities of GenMont Biotech Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$215.35 Million ≈ $6.78 Million |
-5.99% |
| 2024-12-31 | NT$229.06 Million ≈ $7.22 Million |
+12.25% |
| 2023-12-31 | NT$204.06 Million ≈ $6.43 Million |
+2.75% |
| 2022-12-31 | NT$198.59 Million ≈ $6.26 Million |
+14.36% |
| 2021-12-31 | NT$173.65 Million ≈ $5.47 Million |
+32.61% |
| 2020-12-31 | NT$130.95 Million ≈ $4.13 Million |
+6.43% |
| 2019-12-31 | NT$123.04 Million ≈ $3.88 Million |
+28.70% |
| 2018-12-31 | NT$95.60 Million ≈ $3.01 Million |
-26.13% |
| 2017-12-31 | NT$129.41 Million ≈ $4.08 Million |
+4.25% |
| 2016-12-31 | NT$124.14 Million ≈ $3.91 Million |
-6.96% |
| 2015-12-31 | NT$133.43 Million ≈ $4.20 Million |
-7.82% |
| 2014-12-31 | NT$144.76 Million ≈ $4.56 Million |
-73.02% |
| 2013-12-31 | NT$536.49 Million ≈ $16.90 Million |
-5.32% |
| 2012-12-31 | NT$566.61 Million ≈ $17.85 Million |
-3.65% |
| 2011-12-31 | NT$588.06 Million ≈ $18.53 Million |
-6.31% |
| 2010-12-31 | NT$627.66 Million ≈ $19.77 Million |
+609.88% |
| 2009-12-31 | NT$88.42 Million ≈ $2.79 Million |
+23.90% |
| 2008-12-31 | NT$71.36 Million ≈ $2.25 Million |
+51.70% |
| 2007-12-31 | NT$47.04 Million ≈ $1.48 Million |
-20.52% |
| 2006-12-31 | NT$59.18 Million ≈ $1.86 Million |
+152.80% |
| 2005-12-31 | NT$23.41 Million ≈ $737.54K |
+56.97% |
| 2004-12-31 | NT$14.91 Million ≈ $469.87K |
+54.95% |
| 2003-12-31 | NT$9.62 Million ≈ $303.24K |
-- |
About GenMont Biotech Inc
GenMont Biotech Incorporation engages in the research and development, manufacture, and sale of various probiotic health products in Taiwan, Singapore, Mainland Chinese, and internationally. The company offers OEM and ODM services, including functional probiotic raw materials, capsules, powder, tablets, and liquid products. GenMont Biotech Incorporation was founded in 2000 and is based in Tainan … Read more